Scarica l'app Stockscreener
35.04
3.30%
1.12
Precedente Chiudi:
$33.92
Aprire:
$34.11
Volume 24 ore:
56,212
Relative Volume:
1.14
Capitalizzazione di mercato:
$138.01M
Reddito:
$36.84M
Utile/perdita netta:
$-729.00K
Rapporto P/E:
-37.93
EPS:
-0.9237
Flusso di cassa netto:
$-10.02M
1 W Prestazione:
+10.92%
1M Prestazione:
-1.27%
6M Prestazione:
+0.92%
1 anno Prestazione:
+123.33%
Intervallo 1D:
$33.37
$35.06
Intervallo di 1 settimana:
$31.50
$35.06
Portata 52W:
$14.00
$44.00
Vtv Therapeutics Inc Stock (VTVT) Company Profile
Nome
Vtv Therapeutics Inc
Settore
Industria
Telefono
336-841-0300
Indirizzo
3980 PREMIER DR, HIGH POINT, NC
Compare VTVT vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VTVT
Vtv Therapeutics Inc
|
35.04 | 138.01M | 36.84M | -729.00K | -10.02M | -0.9237 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vtv Therapeutics Inc Stock (VTVT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-12 | Iniziato | Evercore ISI | Outperform |
| 2026-01-23 | Iniziato | Roth Capital | Buy |
| 2026-01-05 | Iniziato | TD Cowen | Buy |
| 2025-11-19 | Iniziato | BTIG Research | Buy |
| 2019-05-30 | Iniziato | H.C. Wainwright | Buy |
| 2018-04-10 | Downgrade | Stifel | Buy → Hold |
| 2018-03-08 | Iniziato | ROTH Capital | Buy |
| 2018-02-08 | Iniziato | Northland Capital | Outperform |
| 2016-09-26 | Iniziato | H.C. Wainwright | Buy |
| 2015-09-04 | Iniziato | Canaccord Genuity | Buy |
| 2015-08-24 | Iniziato | Piper Jaffray | Overweight |
| 2015-08-24 | Iniziato | Stifel | Buy |
Mostra tutto
Vtv Therapeutics Inc Borsa (VTVT) Ultime notizie
(VTVT) Volatility Zones as Tactical Triggers - Stock Traders Daily
vTv Therapeutics Inc. Stock 12‑Month Price Target Raised to $54.8, Implies 56% Upside - TradingView
vTv Therapeutics Inc (VTVT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
vTv Therapeutics Inc (VTVT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
vTv Therapeutics Inc (VTVT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
vTv Therapeutics Inc (VTVT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
vTv Therapeutics Inc (VTVT) Institutional Confidence - TradingKey
vTv Therapeutics Inc (VTVT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
vTv Therapeutics Inc (VTVT) Valuation: PE, PB & Fair Value Analysis - TradingKey
vTv Therapeutics Inc (VTVT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
vTv Therapeutics Inc (VTVT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
VTVT Q1 2026 Earnings: Surprise Profit Amid No RevenueEarnings Preview - newsline.com
Price-Driven Insight from (VTVT) for Rule-Based Strategy - Stock Traders Daily
vTv Therapeutics, Inc. Class A Financial Disclosures & SEC Filings - TradingView
VTVT Q1 2026 Earnings: Massive EPS Beat Driven by Non-Operational ItemsForward EPS Estimate - newsline.com
VTVT Technical Analysis | Trend, Signals & Chart Patterns | VTV THERAPEUTICS INC- CL A (NASDAQ:VTVT) - ChartMill
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Stock options, 10-year term: inside vTv Therapeutics grant - Stock Titan
VTVT Stock Price, Quote & Chart | VTV THERAPEUTICS INC- CL A (NASDAQ:VTVT) - ChartMill
MSN Money - MSN
vTv Therapeutics Drops as Diabetes Study Date Approaches - Bez Kabli
vTv Therapeutics (VTVT) Edges Lower, Holding Above Key Support Amid ConsolidationRisk Parity Rebalance - thelegaladvocate.com
(VTVT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
VTVT Q1 2026 Earnings: Massive EPS Surprise Driven by a Non-Recurring GainEarnings Quality Score - The Legal Advocate
vTv Therapeutics Q1 2026 Earnings: Strong EPS Surprise Driven by Non-Operating Items, Stock DeclinesNew Analyst Coverage - newsline.com
VTVT Q1 2026 Earnings: Massive EPS Beat Driven by One-Time Items, Stock DeclinesCEO Earnings Statement - The Legal Advocate
vTv Therapeutics Inc. (VTVT) Slips 3% as Resistance Holds; Traders Eye Support TestLow Beta Factor - newsline.com
vTv Therapeutics Q1 2026 Earnings: Massive EPS Surprise on One-Time Gains, Shares SlipProfit Margin Analysis - newsline.com
vTv Therapeutics Inc. Q1 2026 Earnings: Massive EPS Surprise Amid Revenue Shortfall and Stock DeclineEBITDA Estimate Trend - The Legal Advocate
vTv Therapeutics Inc. (VTVT) Q1 2026 Earnings: Massive EPS Surprise Despite No RevenueAnalyst Stock Picks - Newser
VTVT | vTv Therapeutics Inc. Class Insider Trading - Quiver Quantitative
vTv Therapeutics Inc. (NASDAQ:VTVT) Just Beat Earnings: Here's What Analysts Think Will Happen Next - Yahoo Finance
(VTVT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
vTv Therapeutics (VTVT) Q1 2026 Earnings: EPS $1.65 Beats EstimatesRevenue Report - newser.com
vTv Therapeutics (VTVT) is on the Move, Here's Why the Trend Could be Sustainable - Yahoo Finance
TD Cowen Maintains VTv Therapeutics(VTVT.US) With Buy Rating, Maintains Target Price $67 - Moomoo
Analyst Maintains Buy on vTv Therapeutics, Reiterates Unchanged $49 Price Target Amid Progress of Cadisegliatin Program - TipRanks
H.C. Wainwright cuts vTv Therapeutics stock price target to $45 By Investing.com - Investing.com Nigeria
H.C. Wainwright cuts vTv Therapeutics stock price target to $45 - Investing.com
vTv Therapeutics Inc. Files Form 8-K for Class A Common Stock on Nasdaq – Company Information and SEC Filing Details - Minichart
vTv Therapeutics (VTVT) Reports Strong Q1 Revenue and Trial Prog - GuruFocus
Is vTv Therapeutics (VTVT) 322.2% Overvalued After Q1 2026? EPS - GuruFocus
vTv Therapeutics Expands At-The-Market Share Program Capacity - TipRanks
Recent filings by vTv Therapeutics Inc. to the U.S. Securities and Exchange Commission (SEC) show that the company has increased its allocation of Class A common shares issued under the at-the-market offering (ATM) plan to the full amount. - Bitget
vTv Therapeutics (NASDAQ: VTVT) registers $47.5M ATM to fund cadisegliatin - Stock Titan
vTv Therapeutics (VTVT) expands ATM share offering, files Dechert legal opinion - Stock Titan
vTv Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
vTv Therapeutics Inc. 1Q 2026: Revenue $36.8M, Net income $24.1M — 10-Q Summary - TradingView
Licensing windfall lifts vTv Therapeutics (NASDAQ: VTVT) to Q1 2026 profit and stronger cash - Stock Titan
[8-K] vTv Therapeutics Inc. Reports Material Event - Stock Titan
vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Vtv Therapeutics Inc Azioni (VTVT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):